{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:46:38Z","timestamp":1784396798583,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. In this study we explore the role of miRNAs (MIR) as modulators of chemosensitivity to identify potential biomarkers of response. We find that 41 and 84 microRNA inhibitors enhance the sensitivity of Capan1 and MiaPaCa2 PDAC cells respectively. These include a MIR1307-inhibitor that we validate in further PDAC cell lines. Chemotherapy-induced apoptosis and DNA damage accumulation are higher in MIR1307 knock-out (MIR1307KO) versus control PDAC cells, while re-expression of MIR1307 in MIR1307KO cells rescues these effects. We identify binding of MIR1307 to CLIC5 mRNA through covalent ligation of endogenous Argonaute-bound RNAs cross-linking immunoprecipitation assay. We validate these findings in an in vivo model with MIR1307 disruption. In a pilot cohort of PDAC patients undergoing FOLFIRONX chemotherapy, circulating MIR1307 correlates with clinical outcome.<\/jats:p>","DOI":"10.1038\/s41467-021-27099-6","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:06:20Z","timestamp":1637233580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-183X","authenticated-orcid":false,"given":"Pietro","family":"Carotenuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lampis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-6670","authenticated-orcid":false,"given":"Colin","family":"Rae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaieh","family":"Hedayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Previdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Guzzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vicentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Said-Huntingford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Hahne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hallsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwaida","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wotherspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Kouvelakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Xavier","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Michalarea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-0934","authenticated-orcid":false,"given":"Rosie","family":"Upstill-Goddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-5150","authenticated-orcid":false,"given":"Anguraj","family":"Sadanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-3078","authenticated-orcid":false,"given":"David K.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0362-5597","authenticated-orcid":false,"given":"Andrew V.","family":"Biankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9552-4725","authenticated-orcid":false,"given":"Nigel B.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-739X","authenticated-orcid":false,"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5158-1069","authenticated-orcid":false,"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-3034","authenticated-orcid":false,"given":"Paul","family":"Workman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-5482","authenticated-orcid":false,"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5426-5683","authenticated-orcid":false,"given":"Nicola","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-1259","authenticated-orcid":false,"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"27099_CR1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent, A. et al. Pancreatic cancer. Lancet 378, 607\u2013620 (2011).","journal-title":"Lancet"},{"key":"27099_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403\u20132413 (1997).","journal-title":"J. Clin. Oncol."},{"key":"27099_CR3","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham, D. et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513\u20135518 (2009).","journal-title":"J. Clin. Oncol."},{"key":"27099_CR4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"27099_CR5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"27099_CR6","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-199","volume":"12","author":"PJ Hosein","year":"2012","unstructured":"Hosein, P. J. et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12, 199 (2012).","journal-title":"BMC Cancer"},{"key":"27099_CR7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jso.23392","volume":"108","author":"BA Boone","year":"2013","unstructured":"Boone, B. A. et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J. Surg. Oncol. 108, 236\u2013241 (2013).","journal-title":"J. Surg. Oncol."},{"key":"27099_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jamasurg.2013.2690","volume":"149","author":"BE Kadera","year":"2014","unstructured":"Kadera, B. E. et al. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg. 149, 145\u2013153 (2014).","journal-title":"JAMA Surg."},{"key":"27099_CR9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen, Q. P. et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J. Natl Cancer Inst. 111, 782\u2013794 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"27099_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","volume":"31","author":"S Gourgou-Bourgade","year":"2013","unstructured":"Gourgou-Bourgade, S. et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial. J. Clin. Oncol. 31, 23\u201329 (2013).","journal-title":"J. Clin. Oncol."},{"key":"27099_CR11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.2010.1535","volume":"304","author":"W De Roock","year":"2010","unstructured":"De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812\u20131820 (2010).","journal-title":"JAMA"},{"key":"27099_CR12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958\u2013967 (2009).","journal-title":"N. Engl. J. Med."},{"key":"27099_CR13","first-page":"1073","volume":"12","author":"C Braconi","year":"2012","unstructured":"Braconi, C. & Patel, T. Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr. Cancer Drug Targets 12, 1073\u20131080 (2012).","journal-title":"Curr. Cancer Drug Targets"},{"key":"27099_CR14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11523-018-0580-3","volume":"13","author":"M Ghidini","year":"2018","unstructured":"Ghidini, M. et al. MicroRNAs as mediators of resistance mechanisms to small-molecule tyrosine kinase inhibitors in solid tumours. Target Oncol. 13, 423\u2013436 (2018).","journal-title":"Target Oncol."},{"key":"27099_CR15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.31094","volume":"72","author":"P Carotenuto","year":"2020","unstructured":"Carotenuto, P. et al. Modulation of biliary cancer chemo-resistance thro ugh microRNA-mediated rewiring of the expansion of CD133+ cells. Hepatology 72, 982\u2013996 (2020).","journal-title":"Hepatology"},{"key":"27099_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-0038-1676097","volume":"39","author":"M Salati","year":"2019","unstructured":"Salati, M. & Braconi, C. Noncoding RNA in cholangiocarcinoma. Semin. Liver Dis. 39, 13\u201325 (2019).","journal-title":"Semin. Liver Dis."},{"key":"27099_CR17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/hep.22326","volume":"47","author":"C Braconi","year":"2008","unstructured":"Braconi, C. & Patel, T. MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumours. Hepatology 47, 1807\u20131809 (2008).","journal-title":"Hepatology"},{"key":"27099_CR18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-09-2123","volume":"16","author":"C Braconi","year":"2010","unstructured":"Braconi, C. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin. Cancer Res. 16, 957\u2013966 (2010).","journal-title":"Clin. Cancer Res."},{"key":"27099_CR19","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1038\/onc.2011.193","volume":"30","author":"C Braconi","year":"2011","unstructured":"Braconi, C. et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30, 4750\u20134756 (2011).","journal-title":"Oncogene"},{"key":"27099_CR20","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/gutjnl-2016-312278","volume":"66","author":"P Carotenuto","year":"2017","unstructured":"Carotenuto, P. et al. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut 66, 1268\u20131277 (2017).","journal-title":"Gut"},{"key":"27099_CR21","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.297.17.1901","volume":"297","author":"M Bloomston","year":"2007","unstructured":"Bloomston, M. et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901\u20131908 (2007).","journal-title":"JAMA"},{"key":"27099_CR22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/1078-0432.CCR-11-0679","volume":"18","author":"NB Jamieson","year":"2012","unstructured":"Jamieson, N. B. et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin. Cancer Res. 18, 534\u2013545 (2012).","journal-title":"Clin. Cancer Res."},{"key":"27099_CR23","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1158\/1078-0432.CCR-13-1899","volume":"19","author":"A Li","year":"2013","unstructured":"Li, A. et al. Serum miR-1290 as a marker of pancreatic cancer-response. Clin. Cancer Res. 19, 5252\u20135253 (2013).","journal-title":"Clin. Cancer Res."},{"key":"27099_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1756-9966-32-71","volume":"32","author":"MZ Ma","year":"2013","unstructured":"Ma, M. Z. et al. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation, and clinical significance. J. Exp. Clin. Cancer Res. 32, 71 (2013).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"27099_CR25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.gastro.2013.10.010","volume":"146","author":"AE Frampton","year":"2014","unstructured":"Frampton, A. E. et al. MicroRNAs cooperatively inhibit a network of tumour suppressor genes to promote pancreatic tumour growth and progression. Gastroenterology 146, 268\u201377.e18 (2014).","journal-title":"Gastroenterology"},{"key":"27099_CR26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jama.2013.284664","volume":"311","author":"NA Schultz","year":"2014","unstructured":"Schultz, N. A. et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311, 392\u2013404 (2014).","journal-title":"JAMA"},{"key":"27099_CR27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s13277-015-3844-x","volume":"37","author":"H He","year":"2016","unstructured":"He, H., Tian, W., Chen, H. & Jiang, K. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biol. 37, 1599\u20131607 (2016).","journal-title":"Tumour Biol."},{"key":"27099_CR28","doi-asserted-by":"crossref","first-page":"152606","DOI":"10.1016\/j.prp.2019.152606","volume":"215","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor. Pathol. Res. Pract. 215, 152606 (2019).","journal-title":"Pathol. Res. Pract."},{"key":"27099_CR29","volume":"6","author":"MJ Moore","year":"2015","unstructured":"Moore, M. J. et al. miRNA-target chimeras reveal miRNA 3\u2019-end pairing as a major determinant of Argonaute target specificity. Nat. Commun. 6, 8864 (2015).","journal-title":"Nat. Commun."},{"key":"27099_CR30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fphys.2020.00096","volume":"11","author":"S Gururaja Rao","year":"2020","unstructured":"Gururaja Rao, S., Patel, N. J. & Singh, H. Intracellular chloride channels: novel biomarkers in diseases. Front. Physiol. 11, 96 (2020).","journal-title":"Front. Physiol."},{"key":"27099_CR31","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/MCB.22.11.3610-3620.2002","volume":"22","author":"E Fern\u00e1ndez-Salas","year":"2002","unstructured":"Fern\u00e1ndez-Salas, E. et al. mtCLIC\/CLIC4, an organellular chloride channel protein, is increased by DNA damage and participates in the apoptotic response to p53. Mol. Cell. Biol. 22, 3610\u20133620 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"27099_CR32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mrrev.2015.01.001","volume":"764","author":"MW van Gisbergen","year":"2015","unstructured":"van Gisbergen, M. W. et al. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities, and models. Mutat. Res. Rev. Mutat. Res. 764, 16\u201330 (2015).","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"27099_CR33","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic. Cancer N. Engl. J. Med. 379, 2395\u20132406 (2018).","journal-title":"Cancer N. Engl. J. Med."},{"key":"27099_CR34","doi-asserted-by":"crossref","unstructured":"Ghaneh, P. et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J. Clin. Oncol. 38, 4505 (2020).","DOI":"10.1200\/JCO.2020.38.15_suppl.4505"},{"key":"27099_CR35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.21037\/jgo.2018.04.02","volume":"9","author":"VHF de Jesus","year":"2018","unstructured":"de Jesus, V. H. F. et al. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J. Gastrointest. Oncol. 9, 694\u2013707 (2018).","journal-title":"J. Gastrointest. Oncol."},{"key":"27099_CR36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2019.08.007","volume":"32","author":"SB Dreyer","year":"2020","unstructured":"Dreyer, S. B. et al. Pancreatic cancer: from genome discovery to PRECISION-Panc. Clin. Oncol. 32, 5\u20138 (2020).","journal-title":"Clin. Oncol."},{"key":"27099_CR37","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","volume":"24","author":"A Sehdev","year":"2018","unstructured":"Sehdev, A. et al. Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX. Clin. Cancer Res. 24, 6204\u20136211 (2018).","journal-title":"Clin. Cancer Res."},{"key":"27099_CR38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.21037\/jgo.2019.09.12","volume":"10","author":"S Palacio","year":"2019","unstructured":"Palacio, S. et al. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer. J. Gastrointest. Oncol. 10, 1133\u20131139 (2019).","journal-title":"J. Gastrointest. Oncol."},{"key":"27099_CR39","doi-asserted-by":"publisher","unstructured":"Pea, A., Jamieson, N. B. & Braconi, C. Biology and clinical application of regulatory RNAs in hepatocellular carcinoma. Hepatology https:\/\/doi.org\/10.1002\/hep.31225 (2020).","DOI":"10.1002\/hep.31225"},{"key":"27099_CR40","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.18632\/oncotarget.7208","volume":"7","author":"K Khan","year":"2016","unstructured":"Khan, K. et al. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget 7, 12672\u201312681 (2016).","journal-title":"Oncotarget"},{"key":"27099_CR41","first-page":"5164","volume":"127","author":"A Al-Momany","year":"2014","unstructured":"Al-Momany, A., Li, L., Alexander, R. T. & Ballermann, B. J. Clustered PI(4,5)P2 accumulation and ezrin phosphorylation in response to CLIC5A. J. Cell Sci. 127, 5164\u20135178 (2014).","journal-title":"J. Cell Sci."},{"key":"27099_CR42","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1111\/j.1742-4658.2007.06145.x","volume":"274","author":"H Singh","year":"2007","unstructured":"Singh, H., Cousin, M. A. & Ashley, R. H. Functional reconstitution of mammalian \u2018chloride intracellular channels\u2019 CLIC1, CLIC4 and CLIC5 reveals differential regulation by cytoskeletal actin. FEBS J. 274, 6306\u20136316 (2007).","journal-title":"FEBS J."},{"key":"27099_CR43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2017.04.005","volume":"47","author":"MDPS Idelchik","year":"2017","unstructured":"Idelchik, M. D. P. S., Begley, U., Begley, T. J. & Melendez, J. A. Mitochondrial ROS control of cancer. Semin. Cancer Biol. 47, 57\u201366 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"27099_CR44","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/carcin\/bgs115","volume":"33","author":"KS Suh","year":"2012","unstructured":"Suh, K. S. et al. CLIC4 is a tumour suppressor for cutaneous squamous cell cancer. Carcinogenesis 33, 986\u2013995 (2012).","journal-title":"Carcinogenesis"},{"key":"27099_CR45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res."},{"key":"27099_CR46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmeth.3840","volume":"13","author":"BJ Zarnegar","year":"2016","unstructured":"Zarnegar, B. J. et al. irCLIP platform for efficient characterization of protein-RNA interactions. Nat. Methods 13, 489\u2013492 (2016).","journal-title":"Nat. Methods"},{"key":"27099_CR47","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.18632\/oncotarget.3859","volume":"6","author":"M Ferracin","year":"2015","unstructured":"Ferracin, M. et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 6, 14545\u201314555 (2015).","journal-title":"Oncotarget"},{"key":"27099_CR48","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1053\/j.gastro.2017.10.043","volume":"154","author":"A Lampis","year":"2018","unstructured":"Lampis, A. et al. MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology 154, 1066\u20131079 (2018).","journal-title":"Gastroenterology"},{"key":"27099_CR49","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555\u20131577 (2010).","journal-title":"Br. J. Cancer"},{"key":"27099_CR50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27099-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27099-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27099-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:06:45Z","timestamp":1670004405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27099-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27099"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27099-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. has a consultancy role with Bayer; has received research funding from AstraZeneca, Bayer, BMS, Roche; and travel grants from Bayer and Lilly. N.S. has received research funding from AstraZeneca, BMS, Pfizer; honoraria from Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier; travel\/accommodation from AstraZeneca, BMS, Eli Lilly, Merck, Roche; and has had advisory roles with Pfizer, AstraZeneca, Servier. D.K.C. received research funding from Celgene, AstraZeneca, MSD and Immodulon, and honoraria from Celgene. D.C. has received funding from Amgen, Sanofi, Merrimack, AstraZeneca, Celgene, MedImmune, Bayer, 4SC, Clovis, Eli Lilly, Janssen, Merck; and has an advisory role with OVIBIO. M.F. has received grants from Astellas Pharma and QED Therapeutics; and has advisory roles with Astellas Pharma, Tesaro, and Diaceutics. F.S. received funding from Amal Therapeutics, Bayer, BMS, Dragonfly Therapeutics, Amgen (inst), AstraZeneca (Inst), Bayer (Inst), BMS (Inst), Roche (Inst), Sanofi (Inst), Bayer, Lilly and is Co-Chair EORTC Colon Cancer Task Force. N.V. received honoraria or travel accommodation from Merck Serono, Pfizer, Bayer, Eli-Lilly, and Menarini Silicon Biosystems. P.W. advises and received grants from Astex\u00a0Pharmaceuticals; advises and owns stock in Nextechinvest; is employed and owns stock in Storm Therapeutics; advises CV6 Therapeutics, Black Diamond Therapeutics, and Vividion Therapeutics; received grants from Vernalis and Merck, and owns stock in Chroma Therapeutics. C.B. received honoraria from Incyte. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6738"}}